Education
About Us
Working with TipRanks
Follow Us
Sellas Life Sciences Group (SLS)
NASDAQ:SLS
SLS Stock Chart & Stats
$4.11
-$0.10(-9.43%)
At close: 4:00 PM EST
$4.11
-$0.10(-9.43%)
Day’s Range― - ―
52-Week Range$0.95 - $5.51
Previous CloseN/A
Volume1.43M
Average Volume (3M)5.65M
Market Cap
$756.37M
Enterprise Value$745.31M
Total Cash (Recent Filing)$44.42M
Total Debt (Recent Filing)$599.00K
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Mar 13, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding142,442,250
10 Day Avg. Volume6,460,378
30 Day Avg. Volume5,647,910
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)6.72
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-25.92
Forecast
1Y Price Target
$7.00Price Target Upside70.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
European Collaboration For SLS009Securing IMPACT-AML access creates a durable operational advantage: it expands multi-site European enrollment, leverages established trial infrastructure, and improves capital efficiency. This materially speeds patient recruitment and regulatory footprints versus building sites internally.
Low Financial LeverageA low debt profile reduces mandatory interest and refinancing risk, giving management flexibility to prioritize clinical development. For a clinical-stage biotech, limited leverage preserves optionality for timing financings around milestones and lessens bankruptcy risk from trial delays.
Recent Cash Infusion From WarrantsThe $26.5M proceeds materially extend near-term runway, allowing continued clinical programs without immediate debt issuance. For a pre-revenue biotech, such capital raises can sustain trials to key data readouts, reducing short-term financing pressure and enabling milestone-focused execution.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces repeated external financing, increasing dilution risk and constraining strategic choices. Over the medium term, ongoing burn without revenue stresses the balance sheet and can delay or curtail development if capital markets tighten.
No Material Recurring Revenue; Sustained LossesAs a clinical-stage company with near-zero revenue, profitability depends entirely on successful clinical outcomes or partner deals. The absence of product cash flows makes long-term viability contingent on binary development milestones, heightening execution and financing risk over several quarters.
Dilution And Equity VolatilitySignificant share issuance and historical negative equity indicate recurring dilution as a structural financing mechanism. This erodes existing shareholders' ownership and can complicate future raises or partnerships, making per-share returns highly sensitive to clinical success rather than operational improvements.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $0.95 and its highest was $5.51 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $756.37M.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Mar 13, 2026 which is in 8 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on Nov 12, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.077 by $0.017.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.06.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 142,442,250 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.077. Following the earnings report the stock price went down -2.013%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (70.32% Upside)
$7.00 (70.32% Upside)
Blogger Sentiment
Bullish
SLS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
327.96%
12-Months-Change
Fundamentals
Return on Equity
-84.33%
Trailing 12-Months
Asset Growth
94.51%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SLS Stock 12 Month Forecast
Average Price Target
$7.00
▲(70.32% Upside)
Technical Analysis
Galectin Therapeutics
―
Voyager Therapeutics
―
Tiziana Life Sciences
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Ownership Overview
1.60% Insiders
6.34% Mutual Funds
2.05% Other Institutional Investors
81.34% Public Companies and Individual Investors